BridgeMD
Can patients with atrial fibrillation discontinue anticoagulant therapy after cardiac surgery: The ATLAAC trial
EU CTIS ID: 2022-502986-92-00
What this study is testing
To investigate the risk of stroke, systemic embolisms and major bleeding events with and without anticoagulant therapy in patients with atrial fibrillation, who have previously undergone surgical left atrial appendage closure
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age > 18 years
- Previously undergone any type of cardiac surgical procedure including any type of surgical left atrial appendage closure (use of any of the following techniques; amputation and suture closure, stapler closure, non-amputating suture closure or closure with an approved surgical occlusion device (e.g. AtriClip)) according to the National Patient Register (NPR) or the Western Danish Heart Registry (WDHR) from January 1st 2010 till April 1st 2023
- Documented history of paroxysmal, persistent, or permanent atrial fibrillation or atrial flutter according to the electronic patient record
- Informed consent
You likely can't join if
- Not receiving oral anticoagulant therapy (warfarin/DOAC)
- Patient specific conditions requiring OAC (e.g. mechanical valve, previous pulmonary embolism)
- Renal impairment (estimated glomerular filtration rate < 30)
- Allergy to contrast media
- Pregnancy or breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.